NIAID Online Update - December 12, 2008

NIAID invites the scientific community to help shape a research initiative to further efforts to develop a cure for HIV infection. The initiative will focus on eliminating the low levels of HIV that persist in the blood, even in individuals taking highly effective antiretroviral therapy. To fully explore the potential for HIV eradication, it is critical to understand the source of this residual virus, to identify the molecular mechanisms that facilitate its persistence, and to develop strategies for eliminating the virus or clarify why it cannot be eliminated.

Specifically, NIAID seeks responses to the following questions:

1. What research should be included in this initiative? Describe what new basic information, technologies and resources are needed to make progress in this area. Indicate whether animal models, pilot clinical studies or both should be included.

2. What research should be excluded from this initiative? Describe what approaches have already been or are currently being explored sufficiently.

3. Is there value added to pursuing this research within a collaborative framework, or would the traditional investigator-initiated mechanisms work just as well, or possibly better?

4. What is the optimal configuration for a research collaboration between academia and the private sector to work on this problem? Describe the respective roles and contributions of the partners and how the collaboration should be managed.

Please send your ideas to persistence@niaid.nih.gov. Responses will be accepted until 5:00 pm Eastern Time on January 15, 2009, and will help shape a funding opportunity announcement to be issued in 2009.

For further information, please see the HIV Persistence Request for Information.

Media inquiries can be directed to the NIAID Office of Communications at 301-402-1663, niaidnews@niaid.nih.gov.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

081212
NI081201

Published 2008 - National Institute of Allergy and Infectious Diseases . All material contained in this report is in the public domain and may be used and reprinted without special permission; citation to source, however, is appreciated.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .